Neurofibroma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-08-13
EMA Authorised: Ezmekly (mirdametinib) — Merck Europe B.V.
EU authority authorised Ezmekly (mirdametinib) for Neurofibromatosis type 1 with neurofibromas, including plexiform neurofibroma, under cond…